Michel Duval

The aim of this pilot study was to explore the feasibility, safety, acceptability, and perceived effects of an immersive, multi-platform distraction (virtual reality/smartphone) intervention on pain and anxiety of children undergoing cancer treatment to improve and refine the intervention. Qualitative data were collected through parent journals and semi-structured, in-person child–parent interviews and analyzed using content analysis to evaluate intervention feasibility and perceived effects on child anxiety and pain management. These data were analyzed through content analysis to evaluate feasibility of the intervention and its perceived effects on the child’s anxiety and pain management. Children’s and parents’ satisfaction were evaluated through surveys. Five children aged from 6 to 17 years hospitalized for cancer treatments and their parents, were recruited (n=10, 5 children, 5 parents). No negative side effects or major logistic issues were reported. Child experiences and parent observations are summarized across three categories: “Effects of the Game Experience,” “Logistical Issues,” and “Engagement and Motivation.” Children and their parents were satisfied with the intervention and mentioned that it had a positive effect on anxiety, pain management, social isolation and children’s mood. Results show the potential of a customized avatar in a multiplatform virtual environment for anxiety and pain management of children hospitalized for cancer treatments. Further research is needed with a larger sample size to have a better understanding of the effects of this intervention with this population of patients.

Background: Nonprofit organizations that serve the pediatric oncology community play a crucial role in disseminating quality information that can inform and support people living with childhood cancer, those that work in the field, and others who make key decisions or policies. These registered organizations can be challenging to locate, as the internet is flux with information and resources of varying quality, misinformation, and disinformation. There remains limited understanding of the knowledge mobilization landscape of these organizations in Canada. Objective: This study will provide an overview of the pediatric oncology nonprofit organizational landscape and describe their knowledge mobilization efforts related to dissemination, highlighting existing strengths, gaps, and novel opportunities to strengthen and unite efforts. Methods: A novel environmental scan methodology will be employed to search government and nonprofit organizations’ databases. Independent reviewers will screen the websites of eligible organizations. Extracted data will be descriptively analyzed, geographically sorted, and presented in a tabular form with accompanying narrative. Results: This project received funding in 2024. We anticipate that preliminary results will be available by summer 2025. The search strategy for this study will be completed in the spring of 2025. One key project milestone for this environmental scan includes sharing drafts of the results from this strategy through expert consultations in the spring of 2025. After this milestone, a full set of preliminary results will be available by summer 2025, and the final manuscript will be submitted in fall 2025. Conclusions: The environmental scan will explicate each step of our method to allow others the opportunity to garner understanding from our learnings. Findings will be disseminated to the broader community via social media, directly to the pediatric oncology network in Canada, and globally, through summaries, infographics, presentations, and traditional academic outputs. By doing so, the pediatric oncology community will have information pertinent to navigating these resources, and further steps can be devised to bolster the knowledge mobilization capacity in Canada. International Registered Report Identifier (IRRID): DERR1-10.2196/76787

Finding reliable, evidence-based information and resources concerning pediatric oncology can be a challenge for childhood cancer community members worldwide. The knowledge mobilization activities of civil society organizations around the world can improve the creation and sharing of pertinent informational resources. A comprehensive understanding of all of the civil society organizations that exist, and their knowledge mobilization activities is missing in the extant literature. This environmental scan of online resources will provide a snapshot of civil society organizations that serve the pediatric oncology community around the world and map the different ways that they disseminate information. Through mapping this organizational landscape, our study will highlight existing gaps and propose novel strategies. This novel global environmental scan methodology will outline each step acting as a guide for others seeking to optimize and magnify knowledge mobilization efforts.

A recent measure was developed to assess the Quality of Life (QoL) of young people with advanced cancer and is available for parents and professionals (Advance QoL). The present study aimed to elaborate self-reported versions for children and adolescents with advanced cancer. We adopted a four-phase research plan: (1) to elaborate the Advance QoL questionnaire for youth (8–12 and 13–18 years old) with a team of young research partners; (2) to evaluate the understandability of these versions in a sample of 12 young patients from the target population using cognitive interviews; (3) to assess social validity in the same group using a questionnaire and the content validity index (CVI); and (4) to refine the questionnaires according to these results. Four major themes were identified: (1) issues affecting the understanding of the tool; (2) issues that did not affect the understanding of the tool; (3) modifications to improve the tool; and (4) positive features of the tool. Advance QoL was well received, and feedback was positive. Adjustments were made according to young people’s comments and two self-reported versions are now available. It is essential to measure the key domains of QoL in advanced cancer. Advance QoL self-report versions will help target the specific needs of young people with this condition and their families.

Objectifs : Cette étude rétrospective et transversale vise à comprendre l’expérience à long terme des parents endeuillés en oncologie pédiatrique et les différences du deuil parental en fonction du genre. Matériel et méthodes : Un questionnaire multisectionnel coconstruit avec des cliniciens et intervenants en suivi de deuil a été tenu en ligne en 2018 et 2019. Les participants au sondage étaient des parents dont l’enfant était décédé au service d’hématologie-oncologie du CHU Sainte-Justine 2 à 18 ans auparavant. Des sections spécifiques sur les réactions, les changements et les souvenirs ont fait l’objet d’analyses descriptives. Résultats : Les réponses de 48 parents ont été analysées. Les résultats indiquent que les mères ont tendance à modifier certaines de leurs activités sociales, alors que les pères cherchent plutôt à retrouver leurs habitudes. Les réactions initialement fortes des parents s’atténuent au fil du temps sans disparaître, en particulier la tristesse et les troubles du sommeil. Les parents ont des souvenirs apaisants des interactions et des soins reçus des intervenants en milieux clinique et communautaire même plusieurs années après le décès de leur enfant. Conclusion : L’offre de soutien psychosocial communautaire et professionnel à long terme est pertinente, de même aux besoins des couples et aux besoins individuels des parents en fonction du genre.

Posttransplant leukemia detection before overt relapse is key to the success of immunotherapeutic interventions, as they are more efficient when leukemia burden is low. However, optimal schedule and monitoring methods are not well defined. We report the intensive bone marrow monitoring of minimal residual disease (MRD) using flow cytometry (FC) and nested reverse transcription polymerase chain reaction (RT-PCR) whenever a fusion transcript allowed it and chimerism by PCR at 11 timepoints in the first 2 years after transplant. Seventy-one transplants were performed in 59 consecutive children, for acute myeloid (n = 38), lymphoid (n = 31), or mixed-phenotype (n = 2) leukemia. MRD was monitored in 62 cases using FC (n = 58) and/or RT-PCR (n = 35). Sixty-seven percent of leukemia recurrences were detected before overt relapse, with a detection rate of 89% by RT-PCR and 40% by FC alone. Increased mixed chimerism was never the first evidence of recurrence. Two patients monitored by RT-PCR relapsed without previous MRD detection, one after missed scheduled evaluation and the other 4.7 years post transplant. Among the 22 cases with MRD detection without overt relapse, 19 received therapeutic interventions. Eight (42%) never relapsed. In conclusion, intensive marrow monitoring by RT-PCR effectively allows for early detection of posttransplant leukemia recurrence.

Background: Epstein–Barr virus (EBV) and cytomegalovirus (CMV) infections can have serious consequences during the period of aplasia and lymphopenia following hematopoietic stem cell transplantation (HSCT). Large pediatric cohort studies examining the effect of antiviral prophylaxis against these viruses are scarce. The present study aimed to analyse the potential effect of antiviral prophylaxis (acyclovir and famciclovir) on active post-transplant EBV and CMV infection in a pediatric cohort of allogeneic HSCT recipients. Methods: We used data from the TREASuRE cohort, consisting of 156 patients who had a first allogeneic HSCT, enrolled in four pediatric centers in Canada between July 2013 and March 2017. Follow-up was performed from the time of transplant up to 100 days post-transplant. Adjusted hazard ratio (HR) with 95% confidence intervals (CI) for the association between antiviral prophylaxis with acyclovir and/or famciclovir and EBV and CMV DNAemia was estimated using multivariate Cox regression models. Results: The post-transplant cumulative incidence of EBV and CMV DNAemia at 100 days of follow-up were, respectively, 34.5% (95% CI: 27.6–42.6) and 19.9% (95% CI: 14.5–27.1). For acyclovir, the adjusted hazard ratio (HR) for CMV and EBV DNAemia was 0.55 (95% CI: 0.24–1.26) and 1.41 (95% CI: 0.63–3.14), respectively. For famciclovir, the adjusted HR were 0.82 (95% CI: 0.30–2.29) and 0.79 (95% CI: 0.36–1.72) for CMV and EBV DNAemia, respectively. Conclusion: The antivirals famciclovir and acyclovir did not reduce the risk of post-transplant CMV and EBV DNAemia among HSCT recipients in our pediatric population.

Umbilical cord blood transplantation (UCBT) has been used to treat malignant and non-malignant diseases. UCBT offers the advantages of easy procurement and acceptable partial HLA mismatches, but also shows delayed hematopoietic and immunological recoveries. We postulated that an intrabone (IB) infusion of cord blood could provide a faster short- and long-term engraftment in a pediatric population with malignant and non-malignant hematologic diseases. We conducted this phase I-II single arm, exploratory clinical trial (NCT01711788) from 2012 to 2016 in a single center. Fifteen patients aged from 1.9 to 16.4 years received an IB UCBT. Median time to neutrophils and platelet recoveries were 18 days (range: 13-36 days) and 42 days (range: 26-107 days), respectively. Rate of severe acute GVH grade was low, with only one patient with grade III aGVH. Relapse occurred in 5 patients (38.5%) and TRM occurred in 1 patient. This leads to 6 years EFS and OS of 66.7% and 80% respectively. In conclusion, IB UCBT is safe and well-tolerated in children and hematological recovery compared similarly to the results obtained with IV UCBT.

This systematic review was undertaken to identify risk factors associated with post-transplant Epstein–Barr virus (EBV) active infection and post-transplant lymphoproliferative disease (PTLD) in pediatric and adult recipients of hematopoietic stem cell transplants (HSCT). A literature search was conducted in PubMed and EMBASE to identify studies published until 30 June 2020. Descriptive information was extracted for each individual study, and data were compiled for individual risk factors, including, when possible, relative risks with 95% confidence intervals and/or p-values. Meta-analyses were planned when possible. The methodological quality and potential for bias of included studies were also evaluated. Of the 3362 titles retrieved, 77 were included (62 for EBV infection and 22 for PTLD). The overall quality of the studies was strong. Several risk factors were explored in these studies, but few statistically significant associations were identified. The use of anti-thymocyte globulin (ATG) was identified as the most important risk factor positively associated with post-transplant active EBV infection and with PTLD. The pooled relative risks obtained using the random-effect model were 5.26 (95% CI: 2.92–9.45) and 4.17 (95% CI: 2.61–6.68) for the association between ATG and post-transplant EBV infection and PTLD, respectively. Other risk factors for EBV and PTLD were found in the included studies, such as graft-versus-host disease, type of conditioning regimen or type of donor, but results are conflicting. In conclusion, the results of this systematic review indicate that ATG increases the risk of EBV infection and PTLD, but the link with all other factors is either nonexistent or much less convincing.